Recro Pharma to Participate in Upcoming Investor Conferences
November 08 2018 - 6:00AM
Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty
pharmaceutical company focused on therapeutics for the hospital and
other acute care settings, today announced that Recro Pharma
management will participate in the following upcoming investor
conferences:
- The Jefferies 2018 Global Healthcare Conference on Wednesday,
November 14, 2018 in London.
- The Piper Jaffray 30th Annual Healthcare Conference on
Wednesday, November 28, 2018 at 2:00 pm ET at the Lotte New York
Palace.
A live and archived webcast of the Piper Jaffray
presentation will be available on the Events page of the Company’s
website www.recropharma.com. The webcast will be archived for a
period of 30 days following the conclusion of the event.
About Recro Pharma, Inc.
Recro Pharma is a specialty pharmaceutical
company that operates through two business divisions, an Acute
Care, hospital product division and a revenue-generating contract
development and manufacturing, or CDMO division, located in
Gainesville, GA. The Acute Care division is primarily focused on
developing innovative products for hospital and other acute care
settings. The Company’s lead product candidate is a proprietary
injectable form of meloxicam, a long-acting preferential COX-2
inhibitor. IV meloxicam has successfully completed two pivotal
Phase III clinical efficacy trials, a large double-blind
placebo-controlled Phase III safety trial, four Phase II clinical
efficacy trials, as well as other safety studies. Recro’s Complete
Response to the CRL for IV meloxicam was accepted for filing by the
FDA in early October 2018 and assigned a PDUFA date of March 24,
2019. As injectable meloxicam is in the non-opioid class of
drugs, if approved, the Company believes it has the potential to
overcome many of the issues associated with commonly prescribed
opioid therapeutics, including respiratory depression,
constipation, excessive nausea and vomiting, as well as having no
addictive potential while maintaining meaningful analgesic effects
for relief of pain. The Company’s CDMO division leverages its
formulation expertise to develop and manufacture pharmaceutical
products using its proprietary delivery technologies and other
manufacturing services for commercial and development-stage
partners who commercialize or plan to commercialize these products.
These collaborations can result in revenue streams including
royalties, profit sharing, research and development and
manufacturing fees, which support continued operations for its CDMO
division, and it contributes non-dilutive funding for the
development and pre-commercialization activities of its Acute Care
division.
Cautionary Statement Regarding Forward
Looking Statements
This press release contains forward-looking
statements that involve risks and uncertainties. Such
forward-looking statements reflect Recro's expectations about its
future performance and opportunities that involve substantial risks
and uncertainties. When used herein, the words "anticipate,"
"believe," "estimate," "upcoming," "plan," "target," "intend" and
"expect" and similar expressions, as they relate to Recro or its
management, are intended to identify such forward-looking
statements. These forward-looking statements are based on
information available to Recro as of the date of this press release
and are subject to a number of risks, uncertainties, and other
factors that could cause Recro’s performance to differ materially
from those expressed in, or implied by, these forward-looking
statements. Recro assumes no obligation to update any such
forward-looking statements. Factors that could cause Recro’s actual
performance to materially differ from those expressed in the
forward-looking statements set forth in this press release include,
without limitation: the Company’s ability to resolve the
deficiencies identified by the FDA in the CRL for IV meloxicam;
whether the FDA will approve the Company’s amended NDA for IV
meloxicam and, if approved, the labeling under any such approval;
if the FDA does not approve the Company’s amended NDA, the time
frame otherwise associated with resolving the deficiencies
identified by the FDA in the CRL and whether the FDA will require
additional clinical studies to support the approval of IV meloxicam
and the time and cost of such studies; the Company’s ability to
successfully launch and commercialize IV meloxicam, if approved;
the length, cost and uncertain results and timing of the Company’s
clinical trials, including the Company’s Phase IIIb clinical trials
and any additional clinical trials that the FDA may require in
connection with IV meloxicam; the extent to which IV meloxicam, if
approved, is accepted by the medical community, including
physicians, patients, health care providers and hospital
formularies; the availability of coverage and adequate and timely
reimbursement for IV meloxicam, if approved; the Company’s ability
to raise future financing for continued product development, IV
meloxicam commercialization and the payment of milestones; the
Company’s ability to achieve its financial goals, including
financial guidance; the Company’s ability to pay its debt;
regulatory developments in the United States and foreign countries;
customer product performance and ordering patterns, the performance
of third-party suppliers and manufacturers; and the Company’s
ability to obtain, maintain and successfully enforce adequate
patent and other intellectual property protection. In particular,
there can be no assurance that the FDA will complete its review by
the PDUFA goal date, that the FDA will not require changes or
additional data with respect to the amended NDA or that the FDA
will approve the amended NDA. The forward-looking statements
in this press release should be considered together with the risks
and uncertainties that may affect Recro’s business and future
results included in Recro’s filings with the Securities and
Exchange Commission at www.sec.gov.
CONTACT:
Investor Relations Contact: Argot Partners Natalie Wildenradt /
Claudia Styslinger (212) 600-1902 natalie@argotpartners.com
claudia@argotpartners.com
Recro Pharma, Inc. Ryan D. Lake (484) 395-2436
rlake@recropharma.com
Media Contact: Argot Partners David Rosen (212) 600-1902
david.rosen@argotpartners.com
Recro Pharma (NASDAQ:REPH)
Historical Stock Chart
From Apr 2024 to May 2024
Recro Pharma (NASDAQ:REPH)
Historical Stock Chart
From May 2023 to May 2024